Allogene Therapeutics Inc’s filing revealed that its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $52377.0 on Jun 10 ’25. In the deal valued at $1.42 per share,36,885 shares were sold. As a result of this transaction, MESSEMER DEBORAH M. now holds 107,431 shares worth roughly $0.14 million.
Then, MESSEMER DEBORAH M. bought 36,885 shares, generating $52,391 in total proceeds.
Before that, Yoshiyama Annie sold 9,601 shares. Allogene Therapeutics Inc shares valued at $13,537 were divested by the SVP, Finance at a price of $1.41 per share. As a result of the transaction, Yoshiyama Annie now holds 130,663 shares, worth roughly $0.17 million.
Citizens JMP downgraded its Allogene Therapeutics Inc [ALLO] rating to a Mkt perform from a a Mkt outperform in a research note published recently. A number of analysts have revised their coverage, including Citizens JMP’s analysts, who increased its forecast for the stock in mid March from “a Mkt perform” to “a Mkt outperform”. Piper Sandler started covering the stock on May 31, 2024. It rated ALLO as “an Overweight”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -5.11% to $1.30. Over the last five days, the stock has lost -10.96%. Allogene Therapeutics Inc shares have fallen nearly -38.97% since the year began. Nevertheless, the stocks have fallen -48.82% over the past one year. While a 52-week high of $3.78 was reached on 02/19/25, a 52-week low of $0.86 was recorded on 05/14/25.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 1.2633, which if violated will result in even more drops to 1.2267. On the upside, there is a resistance level at 1.3633. A further resistance level may holdings at 1.4267.
